ONC Delivers Robust Revenue Growth and Pipeline Progress Amid Record Free Cash Flow
40% Annual Revenue Growth Signals Strong Oncology Leadership
BeOne Medicines (NASDAQ: ONC) reported significant growth for the fourth quarter and full year 2025, solidifying its position as a global oncology leader. Total revenue reached $5.34 billion for the year, marking a 40% increase from 2024. The company’s revenue momentum is primarily attributed to the global success of its BTK inhibitor BRUKINSA and expanding indications for TEVIMBRA, both of which have received strong physician adoption and broadening regulatory approvals.
BRUKINSA’s global sales surged to $3.9 billion for the year, up 49%. TEVIMBRA and partnered Amgen products also posted double-digit gains, with TEVIMBRA reaching $737 million (+19%) and Amgen in-licensed assets contributing $486 million (+33%).
Operating Leverage Drives Record GAAP and Adjusted Earnings
The company achieved a remarkable turnaround in profitability, swinging from net losses in 2024 to healthy profits in 2025. GAAP net income came in at $287 million, bouncing back from a $645 million loss the prior year, while adjusted net income soared to $917.6 million from a loss of $54.9 million. Operating leverage improved substantially, with adjusted operating income hitting $1.1 billion—a massive 2325% gain year-over-year.
| Metric | Q4 2025 | Q4 2024 | % Change | FY 2025 | FY 2024 | % Change |
|---|---|---|---|---|---|---|
| Net Product Revenues | $1.48B | $1.12B | +32% | $5.28B | $3.78B | +40% |
| Adjusted Operating Income | $344M | $79M | +338% | $1.10B | $45M | +2325% |
| GAAP Net Income | $66.5M | ($151.9M) | +144% | $287M | ($644.8M) | +145% |
| Free Cash Flow | $380M | ($17.3M) | N/A | $942M | ($633.3M) | N/A |
Efficiency Improvements Underpin Margin and Cash Generation
Gross margin (GAAP) improved to 87.3% for the full year (from 84.3% in 2024), underscoring greater operating efficiency and favorable product mix. On a non-GAAP basis, gross margin grew to 87.8%. Operating expenses grew in line with sales, with R&D investments increasing 10% and SG&A up 14%, reflecting a proactive strategy to support long-term growth while maintaining cost control.
Remarkably, free cash flow soared to $942 million for 2025 from a negative $633 million the previous year, confirming the company’s ability to translate top-line growth into sustainable cash generation—even as it ramps up investment in its pipeline.
2026 Guidance Expects Continued Revenue and Profit Expansion
Looking ahead, BeOne projects total revenue for 2026 in the range of $6.2–$6.4 billion, driven by further BRUKINSA expansion in the U.S. and growth across Europe and other markets. Expected gross margins are set in the high-80% range, and GAAP operating income is forecast at $700–$800 million, with non-GAAP operating income projected at $1.4–$1.5 billion, assuming similar expense growth and no new large business deals.
| Guidance Metric (2026) | Estimated Amount |
|---|---|
| Total Revenue | $6.2–$6.4B |
| GAAP Gross Margin % | High-80% range |
| GAAP Operating Expenses | $4.7–$4.9B |
| GAAP Operating Income | $700–$800M |
| Non-GAAP Operating Income | $1.4–$1.5B |
Diversified Pipeline Targets Next-Generation Oncology Breakthroughs
Beyond its commercial successes, BeOne is making notable advances in its pipeline. The company highlighted landmark clinical results for BRUKINSA from multiple Phase 3 trials, expansion of TEVIMBRA with positive HER2-positive gastric cancer data, and regulatory progress for its BCL2 inhibitor Sonrotoclax. Upcoming milestones in 2026 include key trial readouts and regulatory actions for BRUKINSA, TEVIMBRA, Sonrotoclax, and several novel solid tumor and hematology assets.
Takeaway: Sustainable Growth Supported by Broad Portfolio and Financial Strength
With record revenue and profit gains across the board, and a robust balance sheet boasting $4.6 billion in cash, BeOne Medicines is demonstrating the power of innovative oncology leadership paired with disciplined financial execution. Investors and analysts will be watching the company’s 2026 pipeline milestones and commercial rollout as key tests for its continued leadership and growth prospects in the sector.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI